Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,396 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Terminated Phase 1Phase 2 Interventional Results available

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518
View directory record Official record
Conditions
Ocular Graft vs Host Disease, Dry Eye
Interventions
rhDNase I, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 22, 2026, 1:53 AM EDT
Recruiting Phase 2 Interventional

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

NCT07049848
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Atezolizumab, Doxorubicin Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

NCT00854126
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Solid Cancers
Interventions
GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, placebo, erlotinib HCl
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
177
States / cities
Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

NCT00501891
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Bevacizumab, Metronomic Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Results available

Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

NCT00826618
View directory record Official record
Conditions
Uveitic Cystoid Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Miami, Florida • Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 22, 2026, 1:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00662038
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 84 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

NCT01609140
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
MPSK3169A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

NCT00672243
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Erlotinib + sirolimus
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Radiosurgery and Avastin for Recurrent Malignant Gliomas

NCT01017250
View directory record Official record
Conditions
Malignant Glioma
Interventions
Stereotactic Radiosurgery (SRS), Bevacizumab
Radiation · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

NCT05867121
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

Rituxan With or Without Methotrexate in Psoriatic Arthritis

NCT00509678
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Rituximab
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
La Jolla, California • Stanford, California • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

NCT00586443
View directory record Official record
Conditions
Solid Tumors
Interventions
bevacizumab, everolimus, panitumumab
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
ABT-869 .25 mg/kg, ABT-869 0.10 mg/kg
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

NCT02286843
View directory record Official record
Conditions
Breast Cancer Metastases, HER2 Positive Breast
Interventions
89Zr-trastuzumab, PET/CT scan, 89Zr-pertuzumab
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Results available

Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

NCT00363168
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 22, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

NCT03796013
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Entrectinib Form A, Entrectinib Form C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 22, 2026, 1:53 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

NCT02072226
View directory record Official record
Conditions
Stroke
Interventions
Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 22, 2026, 1:53 AM EDT
Recruiting Phase 2 Interventional

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT05626114
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OpRegen
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 1:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 1:53 AM EDT